EUCTR2011-004223-12-ES
进行中（未招募）
不适用
A pilot, randomised, double blind, placebo-controlled, parallel groups, clinical trial to investigate the efficacy and safety of Cardiotrophin-1 (CT-1) in kidney transplantation.
Digna Biotech S.L.0 个研究点2012年7月26日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Kidney transplantation.
- 发起方
- Digna Biotech S.L.
- 状态
- 进行中（未招募）
- 最后更新
- 11年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •A donor will be suitable only if all of the following criteria apply:
- •1\.Heart\-beating donors (male or female);
- •2\.Donor aged ? 60 or donor aged 50\-59 years and fulfilling 2 of the following 3 criteria:
- •a.Serum creatinine more than 1\.5 mg/dl.
- •b.Death due to cerebrovascular accident.
- •c.History of high blood pressure.
- •A patient (Kidney recipient) will be eligible only if all of the following criteria apply:
- •1\.Males or females aged 18 to 70 years without restricted legal competence and being able to comply with the study requirements.
- •2\.Females of Childbearing Potential must have a negative urine pregnancy test at Screening/Treatment visit and must be willing to use one medically approved form of birth control while on study and for at least 28 days after taking kidney transplant.
- •3\.Subject capable of giving written informed consent.
排除标准
- •A donor will not be suitable if any of the following criteria apply:
- •1\.Infection by HIV, HBV and/or HCV viruses.
- •2\.Non\-heart beating donors.
- •3\.Kidney from a living donor.
- •4\.Cold ischemic time \>24 hours.
- •5\.Incompatible AB0 type with recipient.
- •6\.Positive crossmatch with recipient.
- •7\.Kidney maintained by pulsatile machine perfusion.
- •A patient (recipient) will not be eligible if any of the following criteria apply:
- •1\.Previous or current myelodysplastic or proliferative disorders.
结局指标
主要结局
未指定
相似试验
已完成
不适用
A pilot, double-blind, randomised, placebo-controlled, exploratory study to investigate the safety and effect of calf intestinal Alkaline Phosphatase in patients with SEPsisSepsisInfections and InfestationsOther and unspecified infectious diseasesISRCTN49482187AM-Pharma B.V. (Netherlands)32
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg bid) as adjunctive therapy to acetylcholinesterase inhibitor over a 3-month period in ambulatory patients suffering from mild to moderate Alzheimer’s Disease (EHT 0202/002 protocol).EUCTR2007-005549-39-FREXONHIT
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, crossoverstudy evaluating the efficacy and safety of Vardenafil versusplacebo administered 12, 18 and 24 hours prior to initiation ofsexual intercourse in subjects with ED.ERECTILE DISFUNCTIONMedDRA version: 6.1Level: PTClassification code 10061461EUCTR2004-001549-13-ITGLAXO SMITHKLINE314
进行中（未招募）
1 期
Study to define the optimal dose, to evaluate efficacy, safety and tolerability of self- administered subcutaneous diclofenac sodium 25-50-75mg/1ml in the treatment of an acute migraine attack with headache.Acute migraine attacks with headache.MedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-004828-29-ITIBSA INSTITUT BIOCHIMIQUE SA128
进行中（未招募）
1 期
A pilot study of the use of metformin to reduce airway glucose in COPDChronic obstructive pulmonary diseaseMedDRA version: 21.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001755-12-GBImperial College40